Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861576 | 1.00 | ALOX5AP (0.33) | ALOX5APHSD11B1P2RX7PSEN1PSEN2 | |
| SCHEMBL3864329 | 1.00 | ALOX5AP (0.33) | ALOX5APHSD11B1P2RX7PSEN1PSEN2 | |
| SCHEMBL6556521 | 0.78 | CHRM2 (0.40) | ALOX5APP2RX7BACE1 | |
| SCHEMBL87607 | 0.73 | ALOX5AP (0.38) | ALOX5APHSD11B1P2RX7PSEN1PSEN2 | |
| SCHEMBL3859941 | 0.68 | HSD11B1 (0.42) | ALOX5APHSD11B1P2RX7 | |
| SCHEMBL1769351 | 0.65 | HDAC4 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30929543 | 0.65 | HDAC4 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL625354 | 0.63 | NPC1 (0.44) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1020368 | 0.63 | NPC1 (0.48) | HSD11B1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5485122 | 0.61 | BDKRB1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595338-B2 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1877377-A2 | PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES | Wyeth (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006118955-A2 | PROCESS FOR PREPARING 3,3-DISUBSTITUTED OXINDOLES AND THIO-OXINDOLES | WYETH (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060247441-A1 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247441-A1 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | TPMT, TH, HTR3C | ALOX5AP 692/4885HSD11B1 1580/4885P2RX7 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.